GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Pretax Margin %

Knight Therapeutics (TSX:GUD) Pretax Margin % : 0.66% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Knight Therapeutics's Pre-Tax Income for the three months ended in Sep. 2024 was C$0.6 Mil. Knight Therapeutics's Revenue for the three months ended in Sep. 2024 was C$92.3 Mil. Therefore, Knight Therapeutics's pretax margin for the quarter that ended in Sep. 2024 was 0.66%.

The historical rank and industry rank for Knight Therapeutics's Pretax Margin % or its related term are showing as below:

TSX:GUD' s Pretax Margin % Range Over the Past 10 Years
Min: -14.97   Med: 141.86   Max: 35905.21
Current: -9.17


TSX:GUD's Pretax Margin % is ranked worse than
70.75% of 995 companies
in the Drug Manufacturers industry
Industry Median: 5.23 vs TSX:GUD: -9.17

Knight Therapeutics Pretax Margin % Historical Data

The historical data trend for Knight Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Pretax Margin % Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.00 16.08 2.75 -14.97 -6.70

Knight Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.92 -35.25 -8.25 0.75 0.66

Competitive Comparison of Knight Therapeutics's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Pretax Margin % falls into.



Knight Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Knight Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-21.988/328.199
=-6.70 %

Knight Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=0.608/92.263
=0.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Knight Therapeutics  (TSX:GUD) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Knight Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.
Executives
Sime Armoyan 10% Security Holder
Samira Sakhia Director, Senior Officer
Amal Khouri Senior Officer
Jonathan Ross Goodman Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande Director
Janice Jean Murray Director
Nicolas Sujoy Director
Long Zone Holdings Inc. 10% Security Holder
Arvind Utchanah Senior Officer
Michael Joseph Tremblay Director
James Gale Director
Michael Dehn Director, Senior Officer
Andrew Moor Senior Officer
Patrick Mcclymont Senior Officer
Kevin Drew Nabholz Director

Knight Therapeutics Headlines

No Headlines